Compare Godaddy Inc (GDDY) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs GSK plc — how do they compare? Godaddy Inc trades at $104.37 (market cap $13.07B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 7× Godaddy Inc's market cap, and GSK plc pays a 3.9% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and GSK plc for 93 Days on average.
| GDDY | GSK | |
|---|---|---|
Market Cap | $13.07B | $91.88B |
Volume | 1,831,274 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $135.18 | $61.18 |
52-Week Low | $75.07 | $43.24 |
Typical Hold Time | 64 Days | 93 Days |
Enterprise Value | $15.75B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $103.19, up 6.15% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $4.95B revenue, 17.83% net margin, and consistent earnings beats in recent quarters. However, the stock faces headwinds from multiple securities class action lawsuits alleging misrepresentation of domain contract terms during September 2025-February 2026 period, creating significant legal overhang despite positive operational performance.
While GoDaddy maintains strong profitability and analyst support (58% buy ratings), the legal challenges present substantial near-term risk. The stock trades above consensus price target of $96.20, suggesting limited upside potential. Investors must weigh robust financial performance against litigation uncertainties that could impact shareholder value through settlements or reputational damage.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
